J. Blokken PhD, PharmD

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2024;15(7):302)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2024;15(6):257)

Highlights in myeloid malignancies

SUMMARY

Myeloid malignancies encompass a group of haematopoietic disorders including acute myeloid leukaemia (AML), myeloproliferative neoplasms, and myelodysplastic syndrome (MDS). At EHA 2024, the most recent updates in the area of myeloid malignancies were presented.

(BELG J HEMATOL 2024;15(5):205–10)

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2024;15(4):176–9)

Expanding the therapeutic armamentarium in relapsed/refractory Diffuse Large B-cell Lymphoma

In recent years, the treatment landscape of patients with relapsed or refractory diffuse-large B-cell lymphoma (R/R DLBCL) has changed dramatically. This mini review will briefly discuss the clinical trial data that were obtained with these different options.

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2024;15(2):58–61)

How I treat in 2024: Acute Lymphoblastic Leukaemia and Acute Myeloid Leukaemia

Over the last decades, major advances in the molecular profiling of acute myeloid leukaemia (AML) led to a deeper understanding of its pathophysiology and revealed potential therapeutic opportunities. As a result, the classification of AML subtypes has evolved from a morphological to a molecular and genetic basis. After years of stagnation, we recently witnessed a rapid expansion of the therapeutic armamentarium in this disease. Therefore, Professor Sébastien Anguille from Antwerp University Hospital gave an overview of the recent advances in this setting. On the other side, in acute lymphoblastic leukaemia (ALL), about half of the adult patients who do not achieve a complete molecular response or who subsequently relapse cannot be cured with the current chemotherapy and targeted agents. In recent years, different immune-based therapies emerged, including monoclonal antibodies, bispecific antibodies, CAR-T cell therapy and antibody drug conjugates. These new treatment options were discussed by Professor Nicolas Boissel from the Saint-Louis Hospital in Paris, France.